FDA Issues Not Approvable Letter for NovoCure's Optune Mya
The FDA has issued a 'not approvable' letter to NovoCure (NVCR) regarding its investigational device, Optune Mya. The device was intended for treating adults with non-small cell lung cancer that has metastasized to the brain following targeted radiation. While the FDA raised no concerns regarding the product's safety profile, it cited uncertainty surrounding the degree of clinical benefit provided by the device as the primary reason for withholding approval. NovoCure is currently evaluating the regulator's response and intends to meet with FDA officials to discuss potential paths toward approval that may not require additional clinical studies. Despite this setback, NovoCure continues to see growth in its existing approved Optune product line, including the Gio, Lua, and Pax devices, though the company remains unprofitable despite rising revenues.